Calidi Biotherapeutics, Inc. (CLDI) Balance Sheet
CLDI balance sheet, 2025
December 31, 2025 · U.S. dollars$8.9M assets = $5.1M liabilities + $3.8M equity
Both columns are drawn to the same scale: what CLDI owns equals what it owes plus shareholders’ equity. Hover a block for its value.
CLDI financial health
Descriptive bands, not a rating. Fiscal 2025.
CLDI balance sheet trends, 2020–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $1.9M2020 | $8.9M2025 | +36.8%/yr | |
| Total liabilities | $24.3M2020 | $5.1M2025 | −26.8%/yr | |
| Shareholders’ equity | −$22.5M2020 | $3.8M2025 | — | |
| Cash & short-term investments | $420,0002020 | $5.6M2025 | +67.9%/yr | |
| Total debt | $11.7M2020 | $2.6M2025 | −26.2%/yr | |
| Net cash (debt) | −$11.3M2020 | $3.0M2025 | +$14.3M | |
| Working capital | −$8.4M2020 | $2.3M2025 | +$10.7M | |
| Current ratio | 0.062020 | 1.592025 | +1.53 | |
| Debt / equity | 4.592024 | 0.682025 | −3.90 |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
CLDI assets
CLDI liabilities and equity
CLDI debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
CLDI balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Cash & short-term investments | $5.6M | $9.6M | $2.0M | $372,000 | $2.1M | $420,000 |
| Cash & equivalents | $5.6M | $9.6M | $2.0M | $372,000 | $2.1M | $420,000 |
| Receivables | $0 | $0 | $1.4M | $870 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $656,000 | $636,000 | $894,000 | $413,130 | $603,000 | $93,000 |
| Total current assets | $6.3M | $10.2M | $4.3M | $786,000 | $2.7M | $513,000 |
| Property, plant & equipment (net) | $1.7M | $2.9M | $5.3M | $1.1M | $585,000 | $723,000 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $919,000 | $1.0M | $373,000 | $725,000 | $66,000 | $616,000 |
| Total assets | $8.9M | $14.2M | $10.0M | $2.6M | $3.4M | $1.9M |
| Liabilities | ||||||
| Accounts payable | $595,000 | $2.1M | $2.9M | $2.1M | $624,000 | $822,000 |
| Short-term debt | $1.5M | $4.4M | $1.9M | $5.5M | $5.1M | $5.3M |
| Deferred revenue | — | — | — | — | −$5.1M | $1.7M |
| Total current liabilities | $3.9M | $9.5M | $10.2M | $43.0M | $26.0M | $8.9M |
| Long-term debt | $600,000 | $600,000 | $2.1M | $0 | $0 | $6.4M |
| Lease obligations | $2.0M | $3.3M | $4.4M | $563,000 | $179,000 | $408,000 |
| Other long-term liabilities | $563,000 | $2.1M | $6.0M | $10.0M | $43,000 | $9.1M |
| Total liabilities | $5.1M | $12.2M | $18.3M | $53.0M | $26.0M | $24.3M |
| Shareholders' equity | ||||||
| Common stock & paid-in capital | $1,000 | $2,000 | $4,000 | $2,000 | $2,000 | $2,000 |
| Retained earnings (deficit) | −$141.6M | −$121.7M | −$99.6M | −$70.4M | −$44.9M | −$34.4M |
| Accumulated other comprehensive income | −$13,000 | −$28,000 | −$47,000 | −$14,000 | −$1,000 | $6,000 |
| Minority interest | $0 | $434,000 | $0 | — | — | — |
| Total shareholders' equity | $3.8M | $1.5M | −$8.2M | −$50.4M | −$22.6M | −$22.5M |
| Key figures | ||||||
| Total debt | $2.6M | $7.0M | $7.2M | $6.0M | $5.2M | $11.7M |
| Net cash (debt) | $3.0M | $2.6M | −$5.2M | −$5.6M | −$3.0M | −$11.3M |
| Working capital | $2.3M | $731,000 | −$5.9M | −$42.2M | −$23.2M | −$8.4M |
| Tangible book value | $3.8M | $1.5M | −$8.2M | −$50.4M | −$22.6M | −$22.5M |
| Current ratio | 1.59 | 1.08 | 0.42 | 0.02 | 0.11 | 0.06 |
| Quick ratio | 1.42 | 1.01 | 0.33 | 0.01 | 0.08 | 0.05 |
| Debt / equity | 0.68 | 4.59 | — | — | — | — |
| Equity / assets | 42.4% | 10.8% | −82.2% | −1,942.2% | −666.8% | −1,213.8% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $4.1M | $6.6M | $5.6M | $10.4M | $5.3M | $10.6M | $9.6M | $1.9M | $836,000 | $1.2M | $2.0M | $10.1M |
| Cash & equivalents | $4.1M | $6.6M | $5.6M | $10.4M | $5.3M | $10.6M | $9.6M | $1.9M | $836,000 | $1.2M | $2.0M | $10.1M |
| Receivables | $266,000 | $0 | $0 | $0 | $50,000 | $50,000 | $0 | $0 | $181,000 | $0 | $1.4M | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $1.1M | $722,000 | $656,000 | $653,000 | $720,000 | $878,000 | $636,000 | $324,000 | $608,000 | $693,000 | $894,000 | $1.5M |
| Total current assets | $5.4M | $7.4M | $6.3M | $11.0M | $6.0M | $11.5M | $10.2M | $2.2M | $1.6M | $1.9M | $4.3M | $11.7M |
| Property, plant & equipment (net) | $992,000 | $1.3M | $1.7M | $2.0M | $2.3M | $3.4M | $2.9M | $4.2M | $4.6M | $5.0M | $5.3M | $5.5M |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $784,000 | $896,000 | $919,000 | $989,000 | $969,000 | $144,000 | $1.0M | $217,000 | $227,000 | $506,000 | $373,000 | $1.4M |
| Total assets | $7.2M | $9.6M | $8.9M | $14.0M | $9.4M | $15.1M | $14.2M | $6.7M | $6.4M | $7.4M | $10.0M | $18.6M |
| Liabilities | ||||||||||||
| Accounts payable | $930,000 | $849,000 | $595,000 | $1.1M | $1.2M | $1.2M | $2.1M | $3.6M | $4.5M | $3.9M | $2.9M | $1.5M |
| Short-term debt | $1.2M | $1.5M | $1.5M | $2.3M | $2.2M | $2.5M | $4.4M | $4.3M | $4.2M | $5.4M | $1.9M | $4.4M |
| Deferred revenue | — | — | — | — | — | — | — | $1.4M | $2.5M | — | — | — |
| Total current liabilities | $3.2M | $3.8M | $3.9M | $5.2M | $5.4M | $5.4M | $9.5M | $11.6M | $13.1M | $15.0M | $10.2M | $10.9M |
| Long-term debt | $600,000 | $600,000 | $600,000 | $600,000 | $600,000 | $600,000 | $600,000 | $2.4M | $1.9M | $3.4M | $2.1M | $2.0M |
| Lease obligations | $1.3M | $1.7M | $2.0M | $2.3M | $2.6M | $3.0M | $3.3M | $3.6M | $3.8M | $4.1M | $4.4M | $4.5M |
| Other long-term liabilities | $234,000 | $220,000 | $563,000 | $1.0M | $1.3M | $1.7M | $2.1M | $2.5M | $3.2M | $3.6M | $6.0M | $6.9M |
| Total liabilities | $4.1M | $4.7M | $5.1M | $6.8M | $7.3M | $7.8M | $12.2M | $16.5M | $18.2M | $22.0M | $18.3M | $19.7M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | — | $1,000 | $1,000 | $1,000 | — | $3,000 | $2,000 | $1,000 | $1,000 | $4,000 | $4,000 | $4,000 |
| Retained earnings (deficit) | −$149.9M | −$145.7M | −$141.6M | −$137.6M | −$132.4M | −$126.7M | −$121.7M | −$117.6M | −$112.6M | −$106.8M | −$99.6M | −$91.3M |
| Accumulated other comprehensive income | −$26,000 | −$22,000 | −$13,000 | −$13,000 | −$13,000 | −$26,000 | −$28,000 | −$74,000 | −$27,000 | $11,000 | −$47,000 | −$4,000 |
| Minority interest | — | — | $0 | $280,000 | $312,000 | — | — | — | — | — | — | — |
| Total shareholders' equity | $3.1M | $4.9M | $3.8M | $6.9M | $1.8M | $6.9M | $1.5M | −$10.3M | −$11.8M | −$14.6M | −$8.2M | −$1.1M |
| Key figures | ||||||||||||
| Total debt | $1.9M | $2.3M | $2.6M | $3.1M | $4.0M | $4.7M | $7.0M | $9.0M | $8.7M | $11.7M | $7.2M | $9.8M |
| Net cash (debt) | $2.1M | $4.4M | $3.0M | $7.3M | $1.3M | $5.9M | $2.6M | −$7.1M | −$7.9M | −$10.5M | −$5.2M | $397,000 |
| Working capital | $2.2M | $3.5M | $2.3M | $5.8M | $696,000 | $6.1M | $731,000 | −$9.4M | −$11.4M | −$13.0M | −$5.9M | $814,000 |
| Tangible book value | $3.1M | $4.9M | $3.8M | $6.9M | $1.8M | $6.9M | $1.5M | −$10.3M | −$11.8M | −$14.6M | −$8.2M | −$1.1M |
| Book value per share | $2.21 | — | — | — | — | — | — | — | — | −$4.10 | — | — |
| Shares outstanding | 1.4M | — | — | — | — | — | — | — | — | 3.6M | — | — |
| Current ratio | 1.68 | 1.92 | 1.59 | 2.12 | 1.13 | 2.12 | 1.08 | 0.19 | 0.12 | 0.13 | 0.42 | 1.07 |
| Quick ratio | 1.34 | 1.73 | 1.42 | 2.00 | 1.00 | 1.96 | 1.01 | 0.16 | 0.08 | 0.08 | 0.33 | 0.93 |
| Debt / equity | 0.62 | 0.46 | 0.68 | 0.45 | 2.27 | 0.68 | 4.59 | — | — | — | — | — |
| Equity / assets | 43.5% | 51.5% | 42.4% | 49.3% | 18.9% | 46.1% | 10.8% | −154.5% | −182.7% | −196.8% | −82.2% | −5.9% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 27, 2026); data from EODHD.
CLDI financial position
At the end of fiscal 2025 (December 31, 2025), Calidi Biotherapeutics had total assets of $8.9 million (down 37.5% from a year earlier), total liabilities of $5.1 million and shareholders' equity of $3.8 million. It held $5.6 million in cash and short-term investments against $2.6 million of debt, a net cash position of $3.0 million. Its current ratio was 1.59. In the latest quarter (ended June 30, 2026) total assets were $7.2 million and equity $3.1 million.
Related: CLDI income statement, CLDI cash flow statement, CLDI key metrics. See the CLDI stock overview for the latest quote and news.
CLDI balance sheet FAQ
What are Calidi Biotherapeutics's total assets?
Calidi Biotherapeutics reported total assets of $8.9 million at the end of fiscal 2025 (December 31, 2025), compared with $14.2 million a year earlier.
How much debt does Calidi Biotherapeutics have?
Calidi Biotherapeutics had $2.6 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.68.
How much cash does Calidi Biotherapeutics have?
Calidi Biotherapeutics held $5.6 million in cash and short-term investments at the end of fiscal 2025; with $2.6 million of debt that is net cash of $3.0 million.
What is Calidi Biotherapeutics's book value?
Calidi Biotherapeutics's shareholders' equity (book value) was $3.8 million at the end of fiscal 2025.
What is Calidi Biotherapeutics's current ratio?
Calidi Biotherapeutics had current assets of $6.3 million and current liabilities of $3.9 million, a current ratio of 1.59 (it can cover its short-term obligations).